Commentary · 27 May 2026
Research articlePublished 2012
Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
We investigated the safety of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides in patients with advanced pancreatic cancer that was refractory to chemotherapy. This was a prospective nonrandomized, single-arm, phase I clinical trial with a fixed 2-mg dose of KIF20A and VEGFR1 peptides for patients with advanced unresectable pancreatic cancer. We determined the HLA genotype of the subjects after enrollment, results of which were held by the evaluative committee and kept from both patients and investigators until completion of the study. The primary endpoint was safety of the peptide vaccination with secondary endpoints being the immunological responses and clinical outcome. We compared study endpoints between the HLA-A*2402-positive and HLA-A*2402- negative groups. KIF20A and VEGFR1 peptides were subcutaneously administered on days 1, 8, 15, and 22 within a 28-day treatment cycle. Nineteen patients diagnosed with unresectable pancreatic cancer were enrolled from May 2009 to January 2010 at our Hospital. Twelve of the 19 patients received 4 or more vaccinations (at least one course). No patient had a severe adverse event in relation to this treatment. Findings from evaluation of clinical responses after one course showed that 2 cases had stable disease and 10 progressive disease. The median overall survival time (MST) for the 12 patients was 5.3 months. In the HLA-A*2402-positive group and HLA-A*2402-negative group, the MST was 6.0 months and 2.3 months (p=0.0373), respectively. Results of this study showed that vaccination with KIF20A and VEGFR1 peptides was a safe treatment, might be a promising treatment. This trial was registered with University Hospital Medical Information Network (UMIN) number UMIN000002022.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pancreatic Disorders & Therapy.
Short communication · 27 May 2026
Immunometabolic Interactions in Pancreatic Disease: Crosstalk Between Energy Dysregulation, Immune Activation, and Tissue Dysfunction
Commentary · 27 May 2026
Microvascular Dysfunction in Pancreatic Disorders: Endothelial Injury, Perfusion Failure, and Tissue Consequences
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPancreatic Disorders & Therapy
- SubjectGastroenterology & Hepatology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Junko Kato”
- BylineArticles whose byline prints “Akihito Nagahara”
- BylineArticles whose byline prints “Tomohiro Kodani”
- BylineArticles whose byline prints “Yoshie Higashihara”
- BylineArticles whose byline prints “Yuji Matsumura”
- BylineArticles whose byline prints “Taro Osada”
- BylineArticles whose byline prints “Takashi Yoshizawa”
- BylineArticles whose byline prints “Masafumi Suyama”
